細胞トランスフェクションの世界市場

細胞トランスフェクションの世界市場は2030年までに21億米ドルに達する見込み

2024年に14億米ドルと推定される細胞トランスフェクションの世界市場は、分析期間2024-2030年にCAGR 7.0％で成長し、2030年には21億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるエレクトロポレーション法は、CAGR 5.5%を記録し、分析期間終了時には7億7,310万米ドルに達すると予測されます。リポフェクション法セグメントの成長率は、分析期間でCAGR 8.9％と推定されます。

米国市場は3億7,920万米ドルと推定、中国はCAGR10.7％で成長予測

米国の細胞トランスフェクション市場は、2024年に3億7,920万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを10.7%として、2030年までに4億2,910万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.6%と6.7%と予測されています。欧州では、ドイツがCAGR 4.6%で成長すると予測されています。

世界の細胞トランスフェクション市場- 主要動向と促進要因のまとめ

細胞トランスフェクションが現代のバイオメディカル調査で台頭している理由とは？

細胞トランスフェクションは、分子生物学と遺伝子工学の基礎技術として発展し、生物医学研究と治療開発の各分野における進歩を牽引しています。この方法は、DNA、RNA、CRISPR-Cas9コンポーネントなどの外来核酸を真核細胞に意図的に導入し、遺伝子発現、サイレンシング、編集を容易にします。CRISPRの台頭は、ゲノム研究、機能ゲノミクス、創薬や疾患モデリングに使用される細胞ベースのアッセイの爆発的な成長と密接に結びついています。アカデミックラボ、バイオテクノロジー新興企業、製薬大手のいずれもが、遺伝子ターゲットの検証、治療用タンパク質の設計、ウイルスベクター生産の最適化のためにトランスフェクションに依存しています。

個別化医療と細胞治療の範囲が拡大するにつれ、高度なトランスフェクション技術への関心が高まっています。研究者は現在、トランスフェクションを活用して、がん免疫療法のための免疫細胞（T細胞やNK細胞など）の改変、組換え生物製剤の製造、遺伝子編集疾患モデルの作製を行っています。がん、神経変性、希少遺伝性疾患といった複雑で慢性的な疾患への関心が高まるにつれ、トランスフェクション市場も並行して需要が増加しています。このツールの汎用性により、前臨床研究、治療開発、診断イノベーションのワークフローへの統合が推進されています。

効率性と安全性を向上させる送達方法はどのように進化しているか？

トランスフェクション手法の技術的進歩は、送達効率、細胞生存率、およびスケーラビリティに関する長年の課題に対処しています。化学的ベースのトランスフェクション（リン酸カルシウムや脂質試薬など）や物理的手法（エレクトロポレーションやマイクロインジェクションなど）のような伝統的技術は、細胞毒性を最小限に抑えながら取り込みを改善するために改良されつつあります。新世代の脂質ナノ粒子、高分子キャリア、非ウイルス性ベクターは、特に初代神経細胞や幹細胞のような敏感な細胞種に対して、生体適合性とトランスフェクション効率を向上させています。

一方、エレクトロポレーション技術は大きく進歩し、現在では、再現性のある結果を得るために電圧とパルス時間を正確に制御する、プログラム可能な自動化システムが提供されています。これらは、CAR-T細胞製造のような大規模臨床応用に特に有用です。研究者はまた、相乗効果を狙って物理的技術と化学的技術を組み合わせたハイブリッド・システムも模索しています。非ウイルス性トランスフェクション・システムへのシフトは特に顕著であり、安全性への懸念、使いやすさ、規制上の利点がその原動力となっています。これらの進化した方法は、標的細胞の範囲を拡大し、再現性を向上させ、研究スケジュールを加速させる。

なぜバイオファーマとアカデミアのパートナーシップが採用を加速しているのか？

学術機関とバイオファーマ企業との共同研究のネットワークが拡大し、トランスフェクションの革新と拡大が促進されています。製薬企業は、生物学的製剤や遺伝子治療のパイプラインを迅速に進めるため、トランスフェクションに基づくプラットフォームへの投資を増やしています。同時に、大学や研究病院はハイスループットのトランスフェクション技術を採用し、遺伝子機能や疾患経路をリアルタイムで研究しています。このようなパートナーシップは、市場アクセスを拡大し、製品開発を加速させる合弁事業やライセンシング契約につながることが多いです。

契約研究機関（CRO）や契約開発製造機関（CDMO）もこの争いに参入し、社内に専門知識を持たない顧客にターンキー・トランスフェクション・サービスを提供しています。このようなアウトソーシングの傾向により、中小企業は大規模なインフラを構築することなく最先端の研究に参加できるようになっています。細胞治療や遺伝子治療の規制経路がより明確化されるにつれて、一貫性がありスケーラブルなトランスフェクション方法の必要性が極めて重要になってきています。学術界、産業界、サービスプロバイダー間のこのようなエコシステムの相乗効果により、ワークフローが合理化され、研究および臨床の両方の場面でトランスフェクション技術の採用が広がっています。

市場の絶え間ない成長の原動力は？

細胞トランスフェクション市場の成長は、いくつかの要因によってもたらされています。遺伝子研究の急増と精密医療の台頭は、前臨床研究やトランスレーショナル研究におけるトランスフェクションの普及を促しています。遺伝子治療、モノクローナル抗体産生、ワクチン開発におけるトランスフェクションへのバイオファーマの依存度が高まっており、効率的でスケーラブルかつ安全なデリバリーシステムへの需要が高まっています。さらに、非ウイルス性ベクター、自動化、ハイスループット・フォーマットにおける技術革新により、この技術の適用範囲がより広範な細胞タイプや実験デザインに広がっています。特に腫瘍学や希少疾患治療において、遺伝子編集療法や細胞ベースの治療法のパイプラインが拡大しているため、GMPに準拠した臨床グレードのトランスフェクション・プラットフォームに対するニーズが高まっています。また、学術機関やCRO/CDMOとのパートナーシップの拡大により、知識の移転が促進され、開発コストが削減され、地域を超えてトランスフェクション技術へのアクセスが向上しています。これらの累積的な力が、世界の細胞トランスフェクション市場の力強く持続的な成長を促進しています。

セグメント

方法（エレクトロポレーション法、リポフェクション法、リン酸カルシウム法、ウイルストランスフェクション法、その他の方法）;エンドユーザー（学術・研究機関エンドユーザー、製薬・バイオテクノロジー企業エンドユーザー、契約研究機関エンドユーザー、その他のエンドユーザー）

調査対象企業の例（注目の合計48社）

• Agilent Technologies Inc.
• Altogen Biosystems
• Applied Biological Materials Inc.
• Bio-Rad Laboratories Inc.
• Bio-Techne Corporation
• Boca Scientific Inc.
• Dundee Cell Products Ltd
• Horizon Discovery Group plc
• Lonza Group Ltd
• MaxCyte Inc.
• Merck KGaA
• Mirus Bio LLC
• Molecular Devices
• OriGene Technologies, Inc.
• PerkinElmer Inc.
• Polyplus-transfection SA
• Promega Corporation
• QIAGEN N.V.
• Sartorius AG
• Thermo Fisher Scientific Inc.

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Cell Transfection Market to Reach US$2.1 Billion by 2030

The global market for Cell Transfection estimated at US$1.4 Billion in the year 2024, is expected to reach US$2.1 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Electroporation Method, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$773.1 Million by the end of the analysis period. Growth in the Lipofection Method segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$379.2 Million While China is Forecast to Grow at 10.7% CAGR

The Cell Transfection market in the U.S. is estimated at US$379.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$429.1 Million by the year 2030 trailing a CAGR of 10.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.6% and 6.7% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Cell Transfection Market - Key Trends & Drivers Summarized

Why Is Cell Transfection Gaining Ground in Modern Biomedical Research?

Cell transfection has evolved into a cornerstone technique in molecular biology and genetic engineering, driving progress across a spectrum of biomedical research and therapeutic development. This method enables the intentional introduction of foreign nucleic acids-such as DNA, RNA, or CRISPR-Cas9 components-into eukaryotic cells, facilitating gene expression, silencing, or editing. Its rising prominence is closely tied to the explosive growth in genomic research, functional genomics, and cell-based assays used in drug discovery and disease modeling. Academic labs, biotech startups, and pharmaceutical giants alike depend on transfection to validate gene targets, engineer therapeutic proteins, and optimize viral vector production.

The expanding scope of personalized medicine and cell therapies has intensified interest in advanced transfection technologies. Researchers are now leveraging transfection to modify immune cells (like T cells or NK cells) for cancer immunotherapy, manufacture recombinant biologics, and create gene-edited disease models. As interest in complex and chronic diseases such as cancer, neurodegeneration, and rare genetic disorders surges, the transfection market is seeing a parallel upswing in demand. The versatility of this tool is driving its integration into workflows across preclinical research, therapeutic development, and diagnostic innovation.

How Are Delivery Methods Evolving to Improve Efficiency and Safety?

Technological advances in transfection methodologies are addressing long-standing challenges related to delivery efficiency, cell viability, and scalability. Traditional techniques like chemical-based transfection (e.g., calcium phosphate or lipid reagents) and physical methods (like electroporation or microinjection) are being refined to improve uptake while minimizing cytotoxicity. New-generation lipid nanoparticles, polymeric carriers, and non-viral vectors offer enhanced biocompatibility and transfection efficiency, particularly for sensitive cell types such as primary neurons or stem cells.

Meanwhile, electroporation technology has made considerable strides, now offering programmable, automated systems that precisely control voltage and pulse duration for reproducible results. These are especially useful in large-scale clinical applications like CAR-T cell manufacturing. Researchers are also exploring hybrid systems that combine physical and chemical techniques for synergistic effects. The shift toward non-viral transfection systems is particularly notable, driven by safety concerns, ease of use, and regulatory advantages. These evolving modalities are expanding the range of target cells, improving reproducibility, and accelerating research timelines-key benefits fueling broader market adoption.

Why Are Biopharma and Academic Partnerships Accelerating Adoption?

A growing network of collaborations between academic institutions and biopharma companies is catalyzing innovation and scaling in the transfection landscape. Pharmaceutical companies are increasingly investing in transfection-based platforms to fast-track biologic and gene therapy pipelines. At the same time, universities and research hospitals are employing high-throughput transfection technologies to study gene function and disease pathways in real time. These partnerships often lead to joint ventures or licensing deals that expand market access and accelerate product development.

Contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are also entering the fray, offering turnkey transfection services to clients lacking in-house expertise. This outsourcing trend is enabling smaller firms to participate in cutting-edge research without building extensive infrastructure. As regulatory pathways for cell and gene therapies become more defined, the need for consistent, scalable transfection methods is becoming critical. These ecosystem synergies between academia, industry, and service providers are streamlining workflows and widening the adoption of transfection technologies in both research and clinical settings.

What’s Powering the Unrelenting Growth of the Market?

The growth in the cell transfection market is driven by several factors. The surge in genetic research and the rise of precision medicine are compelling widespread use of transfection in preclinical and translational studies. Biopharma’s increasing reliance on transfection for gene therapy, monoclonal antibody production, and vaccine development is fueling demand for efficient, scalable, and safe delivery systems. Additionally, innovations in non-viral vectors, automation, and high-throughput formats are expanding the technology’s applicability to a broader range of cell types and experimental designs. The expanding pipeline of gene-edited and cell-based therapies-particularly in oncology and rare disease treatment-is intensifying the need for GMP-compliant, clinical-grade transfection platforms. Also, the growth of academic and CRO/CDMO partnerships is facilitating knowledge transfer, reducing development costs, and enhancing access to transfection technologies across geographies. These cumulative forces are driving strong and sustained growth in the global cell transfection market.

SCOPE OF STUDY:

The report analyzes the Cell Transfection market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Method (Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method, Other Methods); End-Use (Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

• Agilent Technologies Inc.
• Altogen Biosystems
• Applied Biological Materials Inc.
• Bio-Rad Laboratories Inc.
• Bio-Techne Corporation
• Boca Scientific Inc.
• Dundee Cell Products Ltd
• Horizon Discovery Group plc
• Lonza Group Ltd
• MaxCyte Inc.
• Merck KGaA
• Mirus Bio LLC
• Molecular Devices
• OriGene Technologies, Inc.
• PerkinElmer Inc.
• Polyplus-transfection SA
• Promega Corporation
• QIAGEN N.V.
• Sartorius AG
• Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Cell Transfection - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Advancements in Gene Editing Technologies Propel Transfection Applications
  • Rising Demand for Recombinant Proteins Enhances Market Growth
  • Development of Non-Viral Transfection Methods Increases Safety Profiles
  • Expansion of Biopharmaceutical Research Drives Equipment Needs
  • Integration of Automation in Transfection Processes Improves Efficiency
  • Growing Use of Transfection in Vaccine Development Spurs Market Demand
  • Investment in Research and Development Fuels Technological Innovations
  • Emergence of Personalized Medicine Increases Transfection Applications
  • Challenges in Transfection Efficiency Highlight Need for Novel Solutions
  • Development of Targeted Delivery Systems Enhances Transfection Specificity
  • Expansion into Emerging Markets Offers New Growth Opportunities
  • Adoption of High-Throughput Screening Methods Boosts Equipment Utilization
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cell Transfection Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cell Transfection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cell Transfection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Cell Transfection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Electroporation Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Electroporation Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for Electroporation Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Lipofection Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Lipofection Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for Lipofection Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Calcium Phosphate Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Calcium Phosphate Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Calcium Phosphate Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Viral Transfection Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Viral Transfection Method by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Viral Transfection Method by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Methods by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Other Methods by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Contract Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cell Transfection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 38: Canada Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: Canada Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 40: Canada 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• JAPAN
  • Cell Transfection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 44: Japan Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Japan Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 46: Japan 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 47: Japan Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Japan Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 49: Japan 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• CHINA
  • Cell Transfection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 50: China Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: China Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 52: China 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 53: China Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: China Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 55: China 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• EUROPE
  • Cell Transfection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Cell Transfection by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Cell Transfection by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Cell Transfection by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 59: Europe Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Europe Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 61: Europe 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 62: Europe Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Europe Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 64: Europe 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• FRANCE
  • Cell Transfection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 65: France Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: France Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 67: France 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 68: France Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 69: France Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 70: France 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• GERMANY
  • Cell Transfection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 71: Germany Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Germany Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 73: Germany 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 74: Germany Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Germany Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 76: Germany 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 77: Italy Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Italy Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 79: Italy 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 80: Italy Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Italy Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 82: Italy 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Cell Transfection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 83: UK Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: UK Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 85: UK 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 86: UK Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: UK Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 88: UK 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 89: Spain Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Spain Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 91: Spain 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 92: Spain Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Spain Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 94: Spain 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 95: Russia Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Russia Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 97: Russia 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 98: Russia Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Russia Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 100: Russia 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Rest of Europe Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 103: Rest of Europe 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Rest of Europe Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 106: Rest of Europe 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Cell Transfection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Cell Transfection by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 108: Asia-Pacific Historic Review for Cell Transfection by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 109: Asia-Pacific 16-Year Perspective for Cell Transfection by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Asia-Pacific Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 112: Asia-Pacific 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Asia-Pacific Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 115: Asia-Pacific 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Cell Transfection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 116: Australia Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Australia Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 118: Australia 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 119: Australia Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Australia Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 121: Australia 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• INDIA
  • Cell Transfection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 122: India Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: India Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 124: India 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 125: India Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: India Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 127: India 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 128: South Korea Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: South Korea Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 130: South Korea 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 131: South Korea Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: South Korea Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 133: South Korea 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Asia-Pacific Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Asia-Pacific Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Asia-Pacific 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Cell Transfection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 140: Latin America Recent Past, Current & Future Analysis for Cell Transfection by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 141: Latin America Historic Review for Cell Transfection by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 142: Latin America 16-Year Perspective for Cell Transfection by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 143: Latin America Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Latin America Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 145: Latin America 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 146: Latin America Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Latin America Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 148: Latin America 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 149: Argentina Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Argentina Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 151: Argentina 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 152: Argentina Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Argentina Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 154: Argentina 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 155: Brazil Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Brazil Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 157: Brazil 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 158: Brazil Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Brazil Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 160: Brazil 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 161: Mexico Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Mexico Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 163: Mexico 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 164: Mexico Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Mexico Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 166: Mexico 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Rest of Latin America Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 169: Rest of Latin America 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Rest of Latin America Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 172: Rest of Latin America 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Cell Transfection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 173: Middle East Recent Past, Current & Future Analysis for Cell Transfection by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 174: Middle East Historic Review for Cell Transfection by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 175: Middle East 16-Year Perspective for Cell Transfection by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 176: Middle East Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Middle East Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 178: Middle East 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 179: Middle East Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Middle East Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 181: Middle East 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 182: Iran Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Iran Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 184: Iran 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 185: Iran Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Iran Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 187: Iran 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 188: Israel Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Israel Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 190: Israel 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 191: Israel Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Israel Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 193: Israel 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Saudi Arabia Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 196: Saudi Arabia 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Saudi Arabia Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 199: Saudi Arabia 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 200: UAE Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: UAE Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 202: UAE 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 203: UAE Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: UAE Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 205: UAE 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Rest of Middle East Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 208: Rest of Middle East 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Rest of Middle East Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 211: Rest of Middle East 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030
• AFRICA
  • Cell Transfection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 212: Africa Recent Past, Current & Future Analysis for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Africa Historic Review for Cell Transfection by Method - Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 214: Africa 16-Year Perspective for Cell Transfection by Method - Percentage Breakdown of Value Sales for Electroporation Method, Lipofection Method, Calcium Phosphate Method, Viral Transfection Method and Other Methods for the Years 2014, 2025 & 2030
  • TABLE 215: Africa Recent Past, Current & Future Analysis for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Africa Historic Review for Cell Transfection by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
  • TABLE 217: Africa 16-Year Perspective for Cell Transfection by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Contract Research Organizations End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION